Unlock stock picks and a broker-level newsfeed that powers Wall Street.

February 2025's Promising Penny Stocks

In This Article:

As global markets navigate a landscape of rising inflation and shifting trade policies, U.S. stock indexes are climbing toward record highs, with growth stocks leading the charge. For investors looking to explore beyond the well-trodden paths of large-cap equities, penny stocks—despite their somewhat antiquated name—remain a compelling area for potential investment. These smaller or newer companies can offer affordability and growth potential when backed by strong financials, making them worth considering in today's market climate.

Top 10 Penny Stocks

Name

Share Price

Market Cap

Financial Health Rating

DXN Holdings Bhd (KLSE:DXN)

MYR0.52

MYR2.59B

★★★★★★

Bosideng International Holdings (SEHK:3998)

HK$3.90

HK$44.77B

★★★★★★

Warpaint London (AIM:W7L)

£3.95

£327.19M

★★★★★★

Begbies Traynor Group (AIM:BEG)

£0.96

£150.13M

★★★★★★

Datasonic Group Berhad (KLSE:DSONIC)

MYR0.335

MYR932.02M

★★★★★★

Polar Capital Holdings (AIM:POLR)

£4.855

£469.93M

★★★★★★

Hil Industries Berhad (KLSE:HIL)

MYR0.855

MYR283.81M

★★★★★★

Foresight Group Holdings (LSE:FSG)

£3.95

£448.86M

★★★★★★

Embark Early Education (ASX:EVO)

A$0.80

A$146.79M

★★★★☆☆

Next 15 Group (AIM:NFG)

£3.09

£305.33M

★★★★☆☆

Click here to see the full list of 5,687 stocks from our Penny Stocks screener.

Let's uncover some gems from our specialized screener.

3D Medicines

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: 3D Medicines Inc. is a biopharmaceutical company focused on researching, developing, and commercializing oncology products for cancer treatment in Mainland China, with a market cap of approximately HK$786.58 million.

Operations: The company's revenue is primarily derived from its biopharmaceutical research and development segment, totaling CN¥488.82 million.

Market Cap: HK$786.58M

3D Medicines Inc., with a market cap of HK$786.58 million, is focused on oncology products in Mainland China. Despite being unprofitable, it has reduced losses by 18.2% annually over five years and maintains a strong cash position exceeding its debt, providing a runway of over three years based on current free cash flow. Recent executive changes include appointing Mr. Ding Gan as chief commercial officer to enhance commercialization efforts, leveraging his extensive industry experience. However, legal challenges have arisen with asset freezes ordered by the Qingdao court amid ongoing litigation that the company is contesting for reconsideration.